Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 10/20 | 0.35 |
| ▸ | UBA3 | Q8TBC4 | 10/20 | 0.35 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27250579 | 1.00 | NAE1 (0.35) | NAE1UBA3ELOVL1S1PR1 | |
| SCHEMBL15024140 | 0.88 | NAE1 (0.36) | NAE1UBA3ELOVL1S1PR1 | |
| SCHEMBL27250596 | 0.85 | NAE1 (0.46) | NAE1UBA3ELOVL1S1PR1 | |
| SCHEMBL12468508 | 0.76 | MCHR1 (0.35) | — | |
| SCHEMBL27250577 | 0.76 | TRPC3 (0.30) | — | |
| SCHEMBL14719969 | 0.75 | NAE1 (0.47) | NAE1UBA3ELOVL1S1PR1 | |
| SCHEMBL27250580 | 0.74 | NAAA (0.40) | — | |
| SCHEMBL27250616 | 0.74 | EGFR (0.49) | NAE1UBA3 | |
| SCHEMBL5402702 | 0.74 | S1PR1 (0.40) | NAE1UBA3ELOVL1S1PR1 | |
| SCHEMBL38661308 | 0.73 | S1PR1 (0.43) | NAE1UBA3ELOVL1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850214-B2 | Inhibitors of NEDD8-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20150011572-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8809356-B2 | Inhibitors of NEDD8-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130150388-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011572-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | NEDD8, NAE1, UBA3 | NAE1 2/4885UBA3 3/4885ELOVL1 3259/4885 |
| US-20130150388-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | NEDD8, NAE1, UBA3 | NAE1 2/4885UBA3 3/4885ELOVL1 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.